Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Recruiting Observational

Mesogastrium Metastasis in Colon Cancer

NCT04980287 · tracked via the Priya Life Science China tracker
Sponsor
Phase
Observational
Started
2021-01-12
Last updated
2026-10-15

Condition(s) studied

Colon Cancer

Study summary

Complete mesocolic excision is currently recognized as a standard procedure for colon cancer. Controversy remains on the presence of right gastroepiploic mesentery metastasis in patients with colon cancer locating at or close to the hepatic flexure. The investigators design this study in order to define the incidence of mesogastrium metastasis and analyse the safety and surgical outcome in these patients who undergo complete mesocolic excision with right gastroepiploic mesentery resection.

Eligibility

Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria: * Age between 18 and 75 years * American Society of Anesthesiologists (ASA) score I to III * A biopsy proven histological diagnosis of colorectal carcinoma * Preoperative staging cT2-4aN0M0 or cTanyN+M0 * tumor located at hepatic flexure or transverse colon close to flexures * Undergoing complete mesocolic excision with right gastric mesentery resection * Patients have to be aware of the aim of the trial, and have signed the informed consent. Exclusion Criteria: * Synchronous colorectal carcinoma * Clinical evidence of metastasis * History of colorectal cancer or other malignant tumors * Preoperative staging cT1N0 or cT4bNany * Emergency procedure

Primary outcome measure(s)

  • metastasis rate — an average of 1 year
    the incidence of gastric mesentery metastasis

Trial sites (1)

FacilityCityRegionStatus
Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology Wuhan Hubei Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04980287 on ClinicalTrials.gov ↗ ← All trials in China